COLUMBIA, Md.--(BUSINESS WIRE)--Osiris Therapeutics, Inc. (NASDAQ:OSIR), a leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, orthopedic and cardiovascular areas, announced today its results for the third quarter ended September 30, 2007. For the quarter, the Company achieved 60% sales growth in its Osteocel product line, secured $30 million in financing commitments, and made significant progress advancing its product pipeline.
